Variation in the fibroblast growth factor 23 (FGF23) gene associates with serum FGF23 and bone strength in infants

被引:1
作者
Enlund-Cerullo, Maria [1 ,2 ,3 ,4 ]
Holmlund-Suila, Elisa [1 ,2 ,4 ]
Valkama, Saara [1 ,2 ,4 ]
Hauta-alus, Helena [1 ,2 ,4 ,5 ,6 ,7 ]
Rosendahl, Jenni [1 ,2 ,4 ]
Andersson, Sture [1 ,2 ]
Pekkinen, Minna [1 ,2 ,3 ,4 ]
Makitie, Outi [1 ,2 ,3 ,4 ,8 ,9 ]
机构
[1] Univ Helsinki, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland
[2] Helsinki Univ Hosp, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland
[3] Folkhalsan Inst Genet, Folkhalsan Res Ctr, Helsinki, Finland
[4] Univ Helsinki, Fac Med, Res Program Clin & Mol Metab, Helsinki, Finland
[5] Natl Inst Hlth & Welf THL, Publ Hlth Res, Helsinki, Finland
[6] Oulu Univ Hosp, PEDEGO Res Unit, MRC Oulu, Oulu, Finland
[7] Univ Oulu, PEDEGO Res Unit, MRC Oulu, Oulu, Finland
[8] Karolinska Univ Hosp, Dept Mol Med & Surg, Stockholm, Sweden
[9] Karolinska Univ Hosp, Karolinska Inst, Ctr Mol Med, Clin Genet, Stockholm, Sweden
基金
瑞典研究理事会; 芬兰科学院;
关键词
FGF23; genetic variation; vitamin D; bone strength; infants (0-24 months); DOMINANT HYPOPHOSPHATEMIC RICKETS; PHYSIOLOGICAL-ROLE; MINERAL DENSITY; VITAMIN-D; PHOSPHATE; MUTATIONS; CHILDREN;
D O I
10.3389/fgene.2023.1192368
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Introduction: The effects of genetic variation in fibroblast growth factor 23 (FGF23) are unclear. This study explores the associations of single-nucleotide polymorphisms (SNPs) of FGF23 with phosphate and vitamin D metabolism and bone strength in early childhood. Methods: The study is part of the vitamin D intervention in infant (VIDI) trial (2013-2016), in which healthy term infants born to mothers of Northern European origin received vitamin D-3 supplementation of 10 or 30 mu g/day from 2 weeks to 24 months of age (ClinicalTrials.gov NCT01723852). Intact and C-terminal FGF23 (cFGF23), 25-hydroxyvitamin D (25-OHD), parathyroid hormone, phosphate, and peripheral quantitative computed tomography (pQCT)-derived bone strength parameters were analyzed at 12 and 24 months. The study included 622 VIDI participants with genotyping data on FGF23 SNPs rs7955866, rs11063112, and rs13312770. Results: Rs7955866 minor allele homozygotes had lowest cFGF23 at both time-points (mixed model for repeated measurements, p(variant) = 0.009). Minor alleles of rs11063112 were associated with a greater age-related decrease in phosphate concentration (p(interaction) = 0.038) from 12 to 24 months. Heterozygotes of rs13312770 had the greatest total bone mineral content (total BMC), cross-sectional area (total CSA), and polar moment of inertia (PMI) at 24 months (ANOVA p = 0.005, 0.037, and 0.036, respectively). Rs13312770 minor alleles were associated with a greater increase of total BMC, but a smaller increase of total CSA and PMI, during follow-up (p(interaction) <0.001, 0.043, and 0.012, respectively). Genotype of FGF23 did not modify 25-OHD. Conclusion: The study finds that genetic variation in FGF23 modifies cFGF23, phosphate, and pQCT-derived bone strength parameters from 12 to 24 months of age. These findings potentially promote an understanding of the regulation of FGF23 and its role in bone metabolism and temporal changes thereof during early childhood.
引用
收藏
页数:18
相关论文
共 42 条
  • [1] Osteocytic FGF23 and Its Kidney Function
    Agoro, Rafiou
    Ni, Pu
    Noonan, Megan L.
    White, Kenneth E.
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [2] A haplotype map of the human genome
    Altshuler, D
    Brooks, LD
    Chakravarti, A
    Collins, FS
    Daly, MJ
    Donnelly, P
    Gibbs, RA
    Belmont, JW
    Boudreau, A
    Leal, SM
    Hardenbol, P
    Pasternak, S
    Wheeler, DA
    Willis, TD
    Yu, FL
    Yang, HM
    Zeng, CQ
    Gao, Y
    Hu, HR
    Hu, WT
    Li, CH
    Lin, W
    Liu, SQ
    Pan, H
    Tang, XL
    Wang, J
    Wang, W
    Yu, J
    Zhang, B
    Zhang, QR
    Zhao, HB
    Zhao, H
    Zhou, J
    Gabriel, SB
    Barry, R
    Blumenstiel, B
    Camargo, A
    Defelice, M
    Faggart, M
    Goyette, M
    Gupta, S
    Moore, J
    Nguyen, H
    Onofrio, RC
    Parkin, M
    Roy, J
    Stahl, E
    Winchester, E
    Ziaugra, L
    Shen, Y
    [J]. NATURE, 2005, 437 (7063) : 1299 - 1320
  • [3] A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis
    Araya, K
    Fukumoto, S
    Backenroth, R
    Takeuchi, Y
    Nakayama, K
    Ito, N
    Yoshii, N
    Yamazaki, Y
    Yamashita, T
    Silver, J
    Igarashi, T
    Fujita, T
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (10) : 5523 - 5527
  • [4] Hormonal regulation of biomineralization
    Arnold, Andrew
    Dennison, Elaine
    Kovacs, Christopher S.
    Mannstadt, Michael
    Rizzoli, Rene
    Brandi, Maria Luisa
    Clarke, Bart
    Thakker, Rajesh V.
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2021, 17 (05) : 261 - 275
  • [5] An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia
    Benet-Pagès, A
    Orlik, P
    Strom, TM
    Lorenz-Depiereux, B
    [J]. HUMAN MOLECULAR GENETICS, 2005, 14 (03) : 385 - 390
  • [6] FGF23 is processed by proprotein convertases but not by PHEX
    Beret-Pagès, A
    Lorenz-Depiereux, B
    Zischka, H
    White, KE
    Econs, MJ
    Strom, TM
    [J]. BONE, 2004, 35 (02) : 455 - 462
  • [7] CORRELATION OF FGF23 AND BALP WITH BONE MINERAL DENSITY IN HEMODIALYSIS PATIENTS
    Bouksila, Mouna
    Mrad, Mehdi
    Kaabachi, Wajih
    Kalai, Eva
    Smaoui, Wided
    Rekik, Sonia
    Krir, Asma
    Issaoui, Nesrine
    Hamzaoui, Kamel
    Sahli, Hela
    El Kateb, Elhem Cheour
    Zouaghi, Mohammed Karim
    Bahlous, Afef
    [J]. JOURNAL OF MEDICAL BIOCHEMISTRY, 2019, 38 (04) : 418 - 426
  • [8] Genome-wide association study for circulating fibroblast growth factor 21 and 23
    Chuang, Gwo-Tsann
    Liu, Pi-Hua
    Chyan, Tsui-Wei
    Huang, Chen-Hao
    Huang, Yu-Yao
    Lin, Chia-Hung
    Lin, Jou-Wei
    Hsu, Chih-Neng
    Tsai, Ru-Yi
    Hsieh, Meng-Lun
    Lee, Hsiao-Lin
    Yang, Wei-shun
    Robinson-Cohen, Cassianne
    Hsiung, Chia-Ni
    Shen, Chen-Yang
    Chang, Yi-Cheng
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [9] Fibroblast growth factor 23 concentrations and modifying factors in children from age 12 to 24 months
    Enlund-Cerullo, Maria
    Hauta-alus, Helena
    Valkama, Saara
    Rosendahl, Jenni
    Andersson, Sture
    Maekitie, Outi
    Holmlund-Suila, Elisa
    [J]. BONE, 2020, 141
  • [10] FGF23-Klotho signaling axis in the kidney
    Erben, Reinhold G.
    Andrukhova, Olena
    [J]. BONE, 2017, 100 : 62 - 68